Comparing the efficacy of Myjet‐assisted tranexamic acid and vitamin C in treating melasma: A split‐face controlled trial. (3rd September 2019)

• Record Type: Journal Article
• Authors: Zhao, Huijuan; Li, Mengna; Zhang, Xiaofeng; Li, Li; Yan, Yan; Wang, Baoxi
• Is Part Of: Journal of cosmetic dermatology. Volume 19:Number 1(2020)
• Page Start: 47
• Page End: 54
• Publication Date: 2019-09-03
• Subjects: meliasma -- tranexamic acid -- transdermal injection -- vitamin C; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.13112
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Background: Melasma is a benign and chronic hypermelanosis characterized by irregular light brown to dark brown patches of hyperpigmentation on the skin. Oral tranexamic acid (TA) or vitamin C (VC) supplementation has been one treatment choice. TA interferes with keratinocyte‐melanocyte interactions, and VC functions by reducing melanin production resulting in skin rejuvenation and whitening. Aim: The aim of the present study was to compare the efficacy and safety of Myjet assisted transdermal injection of TA vs VC in the treatment of melasma. Methods: In this split‐face controlled trial, 17 patients were randomized to receive eight weekly transdermal injections of TA or VC via Myjet either on the right or the left side of their face. MASI was measured from each side of the face at the baseline, at the middle, and at the end of treatment. Results: A reduction in MASI was observed for TA and VC separately ( P value < 0.05). The difference in efficacy between TA and VC group was not statistically significant (P value 0.05). Both treatments were well tolerated, with no serious adverse events reported. Conclusion: Weekly TA or VC transdermal injections can be an effective treatment for melasma. Further studies are required to validate these findings.